Across TCGA pan-cancer cohorts, CRYBA4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CRYBA4 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CRYBA4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CRYBA4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, UCEC, and ESCA are the cancer types where CRYBA4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.110	0.578	.004	24	view →
UCEC	DFS	Median	All	1.000	0.829	.020	14	view →
ESCA	DFS	Median	II,III,IV	0.089	0.522	.001	12	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CRYBA4 tumor-vs-normal RNA expression · all CRYBA4 data types